Center for Biostatistics in AIDS Research, Harvard School of Public Health, Boston, Massachusetts, USA.
Am J Epidemiol. 2012 May 1;175(9):950-61. doi: 10.1093/aje/kwr401. Epub 2012 Apr 6.
The Pediatric HIV/AIDS Cohort Study's Surveillance Monitoring of ART Toxicities Study is a prospective cohort study conducted at 22 US sites between 2007 and 2011 that was designed to evaluate the safety of in utero antiretroviral drug exposure in children not infected with human immunodeficiency virus who were born to mothers who were infected. This ongoing study uses a "trigger-based" design; that is, initial assessments are conducted on all children, and only those meeting certain thresholds or "triggers" undergo more intensive evaluations to determine whether they have had an adverse event (AE). The authors present the estimated rates of AEs for each domain of interest in the Surveillance Monitoring of ART Toxicities Study. They also evaluated the efficiency of this trigger-based design for estimating AE rates and for testing associations between in utero exposures to antiretroviral drugs and AEs. The authors demonstrate that estimated AE rates from the trigger-based design are unbiased after correction for the sensitivity of the trigger for identifying AEs. Even without correcting for bias based on trigger sensitivity, the trigger approach is generally more efficient for estimating AE rates than is evaluating a random sample of the same size. Minor losses in efficiency when comparing AE rates between persons exposed and unexposed in utero to particular antiretroviral drugs or drug classes were observed under most scenarios.
儿科艾滋病队列研究的抗逆转录病毒药物毒性监测研究是一项前瞻性队列研究,于 2007 年至 2011 年在美国 22 个地点进行,旨在评估未感染人类免疫缺陷病毒的儿童在子宫内暴露于抗逆转录病毒药物的安全性,这些儿童的母亲患有艾滋病。这项正在进行的研究采用了“触发式”设计;也就是说,对所有儿童进行初始评估,只有那些达到一定阈值或“触发”的儿童才会接受更深入的评估,以确定他们是否发生了不良事件 (AE)。作者报告了在抗逆转录病毒药物毒性监测研究中每个感兴趣领域的 AE 发生率的估计值。他们还评估了这种基于触发的设计用于估计 AE 发生率和测试抗逆转录病毒药物宫内暴露与 AE 之间关联的效率。作者证明,在对触发识别 AE 的敏感性进行校正后,基于触发的设计估计的 AE 发生率是无偏的。即使不基于触发敏感性校正偏差,触发方法在估计 AE 发生率方面通常比评估相同大小的随机样本更有效。在大多数情况下,在比较宫内暴露于特定抗逆转录病毒药物或药物类别的人与未暴露者的 AE 发生率时,观察到效率略有下降。